Welcome to our dedicated page for Cytosorbents news (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.
CytoSorbents Corporation (NASDAQ: CTSO) generates frequent news flow around its blood purification technologies for intensive care and cardiac surgery. Company updates often center on clinical data, regulatory milestones, and commercial progress for its lead product CytoSorb® and its investigational DrugSorb™-ATR antithrombotic removal system.
Investors following CTSO news can expect announcements on quarterly and annual financial results, including revenue trends, gross margins, and cash flow initiatives, as seen in recent preliminary and reported results. Regulatory developments are another major theme, with detailed disclosures on the De Novo pathway for DrugSorb‑ATR, FDA appeal outcomes, pre‑submission meetings, and anticipated review timelines, as well as interactions with Health Canada.
CytoSorbents also issues news on scientific and medical events, such as presentations at major healthcare and cardiothoracic surgery conferences, company‑sponsored symposia, and global webinars on topics like sepsis and septic shock. These releases highlight new randomized trial results, real‑world evidence, and meta‑analyses involving CytoSorb and DrugSorb‑ATR, along with educational efforts aimed at clinicians in critical care and cardiac surgery.
Additional coverage includes participation in investor conferences, amendments to credit agreements, and workforce and cost reduction programs intended to influence the company’s financial trajectory. For readers tracking CTSO stock, the news stream provides insight into how CytoSorbents is advancing its blood purification platform, pursuing regulatory approvals, and expanding clinical adoption across high‑risk ICU and surgical indications. Bookmark this page to review the latest press releases, event notices, and business updates related to CytoSorbents.
CytoSorbents (NASDAQ: CTSO) reported preliminary, unaudited Q4 2025 revenue of approximately $9.2M and full‑year 2025 revenue of approximately $37.0M (≈4% growth vs. 2024). Q4 gross margin is expected to be 73%–75% and full‑year gross margin approximately 72%. The company surpassed 300,000 cumulative CytoSorb treatments. The pivotal STAR‑T study for DrugSorb‑ATR was accepted for publication and a Pre‑Submission meeting with the FDA is scheduled this month, with an anticipated De Novo filing by end‑Q1 2026 and a regulatory decision expected in mid‑2026. A November 13, 2025 credit amendment added $2.5M of cash and extended interest‑only terms; an additional $2.5M and further extension are conditional on FDA approval. Management expects near operating cash‑flow breakeven in Q1 2026 excluding restructuring payments.
CytoSorbents (NASDAQ: CTSO) announced a virtual fireside chat on December 15, 2025 where CEO Dr. Phillip Chan and CFO Peter J. Mariani will join D. Boral Capital to discuss recent company developments.
Key points highlighted include $37.0 million in trailing 12-month high-margin sales, a strengthened balance sheet, and ongoing regulatory progress for DrugSorb-ATR with an FDA decision expected in mid-2026. The session will expand on Q3 results and near-term milestones shaping the company’s growth trajectory.
Event time: 11:00 AM – 12:00 PM EST, Dec 15, 2025. Registration via D. Boral Capital.
CytoSorbents (NASDAQ: CTSO) will present at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 12:30 PM GMT / 7:30 AM ET.
Management will also hold one-on-one investor meetings during the conference (November 17-20, 2025). A live webcast of the presentation is available via the company website under Events and Presentations, and a replay will be archived for up to 90 days. This release updates the company's November 11, 2025 announcement to add the November 18 presentation.
CytoSorbents (NASDAQ: CTSO) reported Q3 2025 revenue of $9.5M, up 10% year-over-year, with gross margin 70%. Operating loss improved to $2.9M and net loss was $3.2M ($0.05/share); adjusted net loss was $2.6M ($0.04/share). Cash and equivalents were $9.1M on Sept 30, 2025, proforma $11.6M assuming an additional $2.5M term loan.
The company amended its credit agreement to provide an immediate $2.5M term loan, extended interest-only to Dec 31, 2026, and issued 1,428,571 warrants at $0.70. Workforce reduction of ~10% and a restructuring charge up to $900k aim to reach operating cash-flow breakeven in Q1 2026. DrugSorb-ATR De Novo submission is planned in Q1 2026 with an anticipated decision by mid-2026.
CytoSorbents (NASDAQ: CTSO) said its CEO Dr. Phillip Chan and CFO Peter Mariani will attend the Jefferies Global Healthcare Conference in London on November 18-19, 2025.
Management will participate in one-on-one investor meetings; investors can schedule meetings through the conference website. For investor queries, contact the company investor relations team at ir@cytosorbents.com.
CytoSorbents (NASDAQ: CTSO) said it will report third quarter 2025 financial results and recent business highlights after the market close on Thursday, November 13, 2025. Management will host a live conference call, presentation webcast, and Q&A starting at 4:30 PM ET the same day.
Investors may join the live webcast at https://app.webinar.net/g7AGWegQ613. Participants are recommended to dial in about 10 minutes early. An archived recording will be available under the Investor Relations section at https://ir.cytosorbents.com/.
CytoSorbents (NASDAQ: CTSO) announced its upcoming scientific presentations at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Copenhagen, October 8-11, 2025. The event will showcase groundbreaking data for their blood purification technologies CytoSorb® and DrugSorb™-ATR in cardiac surgery applications.
Two significant presentations will be featured: The first randomized trial results of DrugSorb-ATR for removing direct oral anticoagulants during urgent cardiac surgery, and a real-world study showing CytoSorb's effectiveness in reducing bleeding complications in acute coronary syndrome patients undergoing CABG surgery. Additionally, a company-sponsored lunch symposium will discuss hemoadsorption as a safety net in cardiac surgery.
CytoSorbents (NASDAQ: CTSO) provided a regulatory update on DrugSorb-ATR, its FDA Breakthrough Device for blood purification. Following FDA's previous De Novo application denial, the company has received constructive feedback and will submit a new De Novo application with additional real-world data supporting their desired label indication for patients on ticagrelor undergoing urgent CABG surgery.
The FDA found no safety issues with the device and has proposed an expedited path for market authorization. CytoSorbents plans to file a pre-submission meeting request in October 2025, with a formal FDA meeting expected in Q4 2025. A regulatory decision is anticipated by mid-2026. Additionally, the company has withdrawn its Health Canada reconsideration request, planning to submit a new application after gaining clarity from the FDA process.
CytoSorbents Corporation (NASDAQ: CTSO) announces a global webinar titled "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" scheduled for September 10, 2025, at 11:00 AM EDT. The webinar, hosted by CEO Dr. Phillip Chan, will feature international critical care experts sharing insights on using CytoSorb® blood purification therapy to treat sepsis and septic shock.
The distinguished panel includes experts from Switzerland, Hungary, and Germany who will discuss best practices for early and intensive CytoSorb treatment. The agenda covers how CytoSorb complements antibiotics, prevents organ failure, and achieves key treatment goals in sepsis, including controlling inflammation, stabilizing patients, removing toxins, and managing fluid overload.
CytoSorbents Corporation (NASDAQ: CTSO), a company specializing in blood purification for critical care and cardiac surgery, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The presentation is scheduled for September 8, 2025, at 11:30 AM ET at the Lotte New York Palace Hotel in New York.
Investors can access the live presentation through a webcast, and a replay will be available for 90 days on the company's investor relations website.
FAQ
What is the current stock price of Cytosorbents (CTSO)?
What is the market cap of Cytosorbents (CTSO)?
